Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model

Gynecologic Oncology

Volumn 115, Issue 3, 2009, Pages 362-366

  Jandial, Danielle D ^a   Messer, Karen ^a   Farshchi Heydari, Salman ^a   Pu, Minya ^a   Howell, Stephen B ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Carboplatin; Cisplatin; Intraperitoneal chemotherapy; Penetration

Indexed keywords

CARBOPLATIN; CISPLATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOMIC EMISSION SPECTROMETRY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG PENETRATION; FEMALE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; OVARY CARCINOMA; PERITONEAL CAVITY; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALS; CARBOPLATIN; CELL LINE, TUMOR; CISPLATIN; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PLATINUM; TRANSPLANTATION, HETEROLOGOUS;

EID: 70350568146     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.08.028     Document Type: Article

References (14)

1. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19 (2001) 1001-1007
2. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
3. Elit L., Oliver T.K., Covens A., Kwon J., Fung M.F., Hirte H.W., et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer 109 (2007) 692-702
4. Elferink F., Vander Vijgh W.J.F., Klein I., Ten Bokkel Huinink W.W., Dubbleman R., and McVie J.G. Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother. Pharmacol. (1988) 4157-4160
5. Los G., Verdegaal E.M., Mutsaers P.H., and McVie J.G. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother. Pharmacol. 28 (1991) 159-165
6. Markman M., Reichman B., Hakes T., Rubin S., Lewis Jr. J.L., Jones W., et al. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer. Gynecol. Oncol. 50 (1993) 100-104
7. Disaia P.J., Sinkovics J.G., Rutledge F.N., and Smith J.P. Cell-mediated immunity to human malignant cells. Am. J. Obstet. Gynecol. 114 (1972) 979-989
8. Katano K., Safaei R., Samimi G., Holzer A., Tomioka M., Goodman M., et al. Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells. Clin. Cancer Res. 10 (2004) 4578-4588
9. Bookman M.A., McGuire III W.P., Kilpatrick D., Keenan E., Hogan W.M., Johnson S.W., et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J. Clin. Oncol. 14 (1996) 1895-1902
10. Minchinton A.I., and Tannock I.F. Drug penetration in solid tumours. Nat. Rev., Cancer 6 (2006) 583-592
11. Dedrick R.L., Myers C.E., Bungay P.M., and DeVita Jr. V.T. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep. 62 (1978) 1-11
12. Howell S.B., Pfeifle C.E., Wung W.E., and Olshen R.A. Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res. 43 (1983) 1426-1431
13. DeGregorio M.W., Lum B.L., Holleran W.M., Wilbur B.J., and Sikic B.I. Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group. Cancer Chemother. Pharmacol. 18 (1986) 235-238
14. Miyagi Y., Fujiwara K., Kigawa J., Itamochi H., Nagao S., Aotani E., et al. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin-a Sankai Gynecology Study Group (SGSG) study. Gynecol. Oncol. 99 (2005) 591-596